Cargando…
A review on exosomes application in clinical trials: perspective, questions, and challenges
BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483361/ https://www.ncbi.nlm.nih.gov/pubmed/36123730 http://dx.doi.org/10.1186/s12964-022-00959-4 |
_version_ | 1784791654445613056 |
---|---|
author | Rezaie, Jafar Feghhi, Maryam Etemadi, Tahereh |
author_facet | Rezaie, Jafar Feghhi, Maryam Etemadi, Tahereh |
author_sort | Rezaie, Jafar |
collection | PubMed |
description | BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases. METHODS: In this review study, we studied numerous articles over the past two decades published on application of exosomes in different diseases as well as on perspective and challenges in this field. RESULTS: The main clinical application of exosomes are using them as a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis for exosome kinetics, and cancer vaccine. Different exosomes from human or plant sources are utilized in various clinical trials. Most researchers used exosomes from the circulatory system for biomarker experiments. Mesenchymal stem cells (MSCs) and dendritic cells (DCs) are two widely held cell sources for exosome use. MSCs-derived exosomes are commonly used for inflammation treatment and drug delivery, while DCs-exosomes are used to induce inflammation response in cancer patients. However, the clinical application of exosomes faces various questions and challenges. In addition, translation of exosome-based clinical trials is required to conform to specific good manufacturing practices (GMP). In this review, we summarize exosomes in the clinical trials according to the type of application and disease. We also address the main questions and challenges regarding exosome kinetics and clinical applications. CONCLUSIONS: Exosomes are promising platforms for treatment of many diseases in clinical trials. This exciting field is developing hastily, understanding of the underlying mechanisms that direct the various observed roles of exosomes remains far from complete and needs further multidisciplinary research in working with these small vesicles. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00959-4. |
format | Online Article Text |
id | pubmed-9483361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94833612022-09-19 A review on exosomes application in clinical trials: perspective, questions, and challenges Rezaie, Jafar Feghhi, Maryam Etemadi, Tahereh Cell Commun Signal Review BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases. METHODS: In this review study, we studied numerous articles over the past two decades published on application of exosomes in different diseases as well as on perspective and challenges in this field. RESULTS: The main clinical application of exosomes are using them as a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis for exosome kinetics, and cancer vaccine. Different exosomes from human or plant sources are utilized in various clinical trials. Most researchers used exosomes from the circulatory system for biomarker experiments. Mesenchymal stem cells (MSCs) and dendritic cells (DCs) are two widely held cell sources for exosome use. MSCs-derived exosomes are commonly used for inflammation treatment and drug delivery, while DCs-exosomes are used to induce inflammation response in cancer patients. However, the clinical application of exosomes faces various questions and challenges. In addition, translation of exosome-based clinical trials is required to conform to specific good manufacturing practices (GMP). In this review, we summarize exosomes in the clinical trials according to the type of application and disease. We also address the main questions and challenges regarding exosome kinetics and clinical applications. CONCLUSIONS: Exosomes are promising platforms for treatment of many diseases in clinical trials. This exciting field is developing hastily, understanding of the underlying mechanisms that direct the various observed roles of exosomes remains far from complete and needs further multidisciplinary research in working with these small vesicles. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00959-4. BioMed Central 2022-09-19 /pmc/articles/PMC9483361/ /pubmed/36123730 http://dx.doi.org/10.1186/s12964-022-00959-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Rezaie, Jafar Feghhi, Maryam Etemadi, Tahereh A review on exosomes application in clinical trials: perspective, questions, and challenges |
title | A review on exosomes application in clinical trials: perspective, questions, and challenges |
title_full | A review on exosomes application in clinical trials: perspective, questions, and challenges |
title_fullStr | A review on exosomes application in clinical trials: perspective, questions, and challenges |
title_full_unstemmed | A review on exosomes application in clinical trials: perspective, questions, and challenges |
title_short | A review on exosomes application in clinical trials: perspective, questions, and challenges |
title_sort | review on exosomes application in clinical trials: perspective, questions, and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483361/ https://www.ncbi.nlm.nih.gov/pubmed/36123730 http://dx.doi.org/10.1186/s12964-022-00959-4 |
work_keys_str_mv | AT rezaiejafar areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges AT feghhimaryam areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges AT etemaditahereh areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges AT rezaiejafar reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges AT feghhimaryam reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges AT etemaditahereh reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges |